Drug intelligence / Profile preview

adderall xr

Development stage
Approved
Lead developer
Takeda
Modality
Small Molecules, Drug Delivery Systems
Administration
Oral
01

Overview

Adderall XR is a central nervous system (CNS) stimulant medication formulated as an extended-release capsule containing four different amphetamine salts: dextroamphetamine saccharate, dextroamphetamine sulfate, amphetamine aspartate monohydrate, and amphetamine sulfate. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older. The drug works primarily by increasing synaptic concentrations of dopamine and norepinephrine through inhibition of their reuptake into presynaptic neurons. This action enhances neurotransmission in brain regions involved in attention and impulse control. Adderall XR provides a double-pulsed delivery system for prolonged therapeutic effect throughout the day[1][2][4][5].

Brand names
Adderall XR
Other names
amphetamine and dextroamphetamine extended-releasemixed amphetamine salts extended-releaseamphetamine salt combo XR
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DAT (Dopamine plasma membrane transport protein)MAOA (Monoamine oxidase A)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)TAAR1 (Trace amine-associated receptor 1)VMAT2 (Vesicular monoamine transporter 2)

Beyond the preview

Go deeper on adderall xr.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on adderall xr.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call